Brought to you by 
Boston Scientific, Corautus terminate gene therapy deal
17 Apr 2007
Executive Summary
Boston Scientific and cardiac/vascular gene therapy company Corautus Genetics (formed through the September 2002 merger of Genstar Therapeutics and Vascular Genetics; originally called Autus Genetics) are collaborating to develop a gene therapy delivery system for cardiovascular disease.
Deal Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Medical Devices
- Surgical Equipment & Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific, Corautus terminate gene therapy deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice